Higher HSPG2 expression implied poor prognosis, which was also observed in the Non-M3 cohort (OS: P < 0.001, Fig. 4b; LFS: P = 0.025, Fig. 4e) and CN-AML patients (OS: P = 0.039, Fig. 4c; LFS: P = 0.056, Fig. 4f). Here, HSPG2 is linked to acute myeloid leukemia.